Information Provided By:
Fly News Breaks for July 25, 2019
ONTX
Jul 25, 2019 | 09:10 EDT
Noble Capital analyst Ahu Demir initiated Onconova with an Outperform rating and $12 price target, noting that the company's Phase 3 INSPIRE study of rigosertib in patients with high-risk myelodysplastic syndrome is expected to have a data readout in 2020. While the company's main focus is MDS, Demir sees it having promising early stage opportunities beyond MDS, he noted. He believes the current stock price does not reflect the potential of Onconova's pipeline, Demir added.
News For ONTX From the Last 2 Days
There are no results for your query ONTX